VERIFIEDMint Companies·22 May 2026neutral

Sun Pharma guides for slower FY27 growth amid regulatory, macro challenges

AI Summary

·Sun Pharma expects high single-digit revenue growth for FY27.
·The company saw an 11.9% revenue increase in FY26.
·Sun Pharma is navigating regulatory challenges and focusing on the obesity-drug market.